The twice yearly lenacapavir injection will be available in 120 countries with a series of regulatory filings beginning by the end of this year.
HIV injection © auremar - stock.adobe.com
Gilead Sciences signed noninclusive, royalty free voluntary licensing agreements with six pharmaceutical manufacturers in Asia and North Africa this week to make and sell generic lenacapavir in 120 high-incidence, primarily low-income countries. While broad, critics say greater access is needed.
The laboratories named in the agreement are:
These drug makers will not be charged for the licenses, according to a news release. These agreements cover lenacapavir as part of a preexposure prophylaxis (PrEP) regimen and as an HIV treatment in adults with treatment resistance HIV.
The top 18 countries that account for 70% of global HIV cases are included as part of the 120 countries. They are:
This partnership comes less than a month after results of a second phase 3 clinical trial revealed that 99.9% of the 2,180 total participants treated with lenacapavir did not acquire HIV.
Lenacapavir was approved by the FDA in December 2022 as an HIV treatment. It is given in combination with other antiretrovirals. Treatment begins with an injection and tablets followed by an injection every six months. Gilead currently charges patients $42,250 per year. There is currently no information about how much it will cost as part of a PrEP regimen.
“The agreements advance Gilead’s strategy to enable broad, sustainable access to lenacapavir for preexposure prophylaxis (PrEP) globally if it is approved,” Daniel O’Day, chairman and CEO of Gilead said in the news release.
However, this deal leaves out most middle- and high- income countries including Brazil, Columbia, Mexico, China and Russia that, when combined, account for about 20% of global HIV infections.
People’s Medicines Alliance, an advocacy group, released the following statement in reaction:
“Behind the seemingly large numbers of countries included in the license, Gilead is largely abandoning upper-middle-income countries, where new infections are highest, with nearly all of Latin America left out,” Mohga Kamal-Yanni, M.D., policy co-lead for the People’s Medicines Alliance, said in a news release. “The countries that have been excluded can use their legal rights to overcome intellectual property restrictions with a compulsory license. However, Gilead’s agreement prevents the six licensee companies from selling to those countries.”
There are currently about 40 million people living with HIV around the world. Last year, an estimated 1.3 million were diagnosed with HIV and about 630,000 died, the WHO reports.
FDA Accepts NDA for Gilead's New HIV Prevention Shot
February 18th 2025Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving this drug a priority review and expects to make a decision by June 19, 2025, according to a release.
Read More
HIV + Hepatitis Institute Welcomes RFK, Talks Importance of Ending the HIV Epidemic
February 13th 2025The group released a statement today expressing that they are eager to work with Robert F. Kennedy Jr. to eradicate HIV when steps into his role as the Secretary of Health and Human Services.
Read More
Trump Administration Throws U.S. AIDS Support into Turmoil
February 6th 2025PEPFAR, the main U.S.-funded global AIDS program was given a waiver from the foreign aid freeze, but there is still uncertainty and interruptions, partly because many PEPFAR programs are implemented through USAID, which has been largely shutdown by the news administration.
Read More
RFK Jr. and HIV Denial: He Says He Is Neutral, But...
January 29th 2025In 2021 book attacking Anthony Fauci, M.D., Robert F. Kennedy Jr. casts doubt on HIV being the sole cause of AIDS and presents arguments made by "HIV deniers" that believe it is bystander in the immunosuppression that characterizes AIDS.
Read More